2017
A first Czech analysis of 1887 cases with monoclonal gammopathy of undetermined significance
SANDECKÁ, Viera; Roman HÁJEK; Luděk POUR; I. SPICKA; V. SCUDLA et. al.Základní údaje
Originální název
A first Czech analysis of 1887 cases with monoclonal gammopathy of undetermined significance
Autoři
SANDECKÁ, Viera; Roman HÁJEK; Luděk POUR; I. SPICKA; V. SCUDLA; E. GREGORA; J. RADOCHA; L. WALTEROVA; P. KESSLER; L. ZAHRADOVA; D. ADAMOVA; K. VALENTOVA; I. VONKE; J. OBERNAUEROVA; D. STAROSTKA; M. WROBEL; Lucie BROŽOVÁ; Jiří JARKOVSKÝ ORCID; Aneta MIKULÁŠOVÁ; L. RIHOVA; Sabina ŠEVČÍKOVÁ; J. STRAUB; J. MINARIK; Zdeněk ADAM; Marta KREJČÍ; Zdeněk KRÁL a V. MAISNAR
Vydání
European Journal of Haematology, Hoboken, Wiley-Blackwell, 2017, 0902-4441
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30205 Hematology
Stát vydavatele
Spojené státy
Utajení
není předmětem státního či obchodního tajemství
Impakt faktor
Impact factor: 2.595
Kód RIV
RIV/00216224:14110/17:00098729
Organizační jednotka
Lékařská fakulta
UT WoS
000403724300010
EID Scopus
2-s2.0-85018904802
Klíčová slova anglicky
monoclonal gammopathy; multiple myeloma; progression; risk factors
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 18. 3. 2018 16:41, Soňa Böhmová
Anotace
V originále
IntroductionMonoclonal gammopathy of undetermined significance (MGUS) is a premalignant condition with a risk of malignant conversion. Patients and methodsWith the aim to estimate the cumulative risk MGUS progression to hematologic malignancies, we analyzed a nationwide population-basedcohort of 1887 MGUS patients from the Czech Registry of Monoclonal Gammopathies (RMG) between 2007 and 2013. ResultsDuring the follow-up period (median 4years; range 0.6-34.8), progression to hematologic malignancies was observed in 8.6% (162 of 1887) of patients. Factors associated with progression were as follows: M-protein concentration 1.5g/dL, pathological sFLC (<0.26 or >1.65) ratio, bone marrow plasma cells (BMPCs) in cytology >5%, immunoparesis, age 69years, and the level of serum hemoglobin at baseline <12.0g/dL. Combining these factors, we propose a new risk model (CMG model). The risk of progression at 10years was 1.6%, 16.9%, 22.9%, 39.4%, and 52.3%, respectively, if 0 (reference group), one, two, three, or four to five risk factors are present (P<.001) with HR 63 times higher compared to the reference MGUS group. ConclusionThe new CMG model was established with an advantage for better identification of MGUS patients at low risk.